Join Professors Matthias Augustin and Sarina Elmariah for an engaging ADVENT symposium as they explore the pivotal role of type 2 inflammation in prurigo nodularis and chronic itch.

Dr. Paller presents the Pediatric Eczema Elective Registry (PEER) findings, which suggest early-onset of AD is associated with higher risk of persistence of disease.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof Oscar Palomares highlights the substantial impact of type 2 inflammatory diseases on the quality of life of patients and their caregivers.

An interactive patient case tool involving a deeper dive into assessing clinical presentation when diagnosing bullous pemphigoid (BP)
At ATS 2026, the Sanofi & Regeneron ADVENT Booth brings together interactive experiences and educational resources to explore Type 2 inflammation as a key feature underlying both asthma and COPD.

Dr. Ramien discusses the role of type 2 inflammation in the pathophysiology of atopic dermatitis, and highlights the association of atopic dermatitis with systemic diseases and comorbidities.
Hear from Drs. Jason Lee, Kathryn Peterson, Seema Aceves, and Ikuo Hirano on disease progression and the importance of managing fibrostenotic risk in EoE.

Understand the drivers of lung function decline in chronic obstructive pulmonary disease (COPD), including chronic inflammation, key risk factors, and the impact on patient well-being .
This symposium highlights type 2 inflammation as a key driver of chronic itch and the characteristic skin lesions of prurigo nodularis and evaluates the real-world implications of targeted therapies on clinical practice.

Embark on this interactive triathlon challenge to uncover the interplay of type 2 inflammation, barrier dysfunction, and neuroimmune dysregulation in the disease pathology of CRSwNP.

Professors Klaus Rabe, Paola Rogliani, and Dr. Stephanie Christenson explore the complexity of inflammatory pathways and phenotypes in COPD. They provide insights into the genetic association of IL-33 with COPD, discuss preclinical findings, and review ongoing clinical research targeting IL-33 in COPD.